Bradley C. Carthon, MD, PhD
Assistant Professor, Hematology & Medical Oncology
Emory University School of Medicine
Office: The Emory Clinic, Bldg. B
Phone: (404) 778-3126
For all patient inquiries or appointment requests, please dial (404) 778-1900. Fax patient records to (404) 778-2177.
Dr. Carthon conducted his PhD thesis work in the Sicinski Laboratory of the Dana Farber Cancer Institute and Harvard Medical School. His research focused on the individual roles of D-type cyclins in the context of mammary gland development and breast cancer, as cyclin had been shown to be overexpressed in various malignancies, including breast cancer. Utilizing knock-in murine mouse models, Dr. Carthon was able to express various D-type cyclins under the control of the cyclin D1 promoter in order to delineate whether the specific roles of D-type cyclins were due to inherent differences in the family of proteins, or if the differences in the D-type cyclins were due predominantly to tissue specific patterns of expression. Animals expressing cyclin D2 under the control of the cyclin D1 promoter were able to develop normally, and lacked many of the phenotypic abnormalities seen in cyclin D1 null animals. This suggested that the specificity of the D type cyclins were largely controlled by tissue specific expression, and differences in cofactors that bound to each of the D-type cyclin signaling complexes.
Research from Dr. Carthon's clinical fellowship was done in the Thompson Lab at the University of Texas M.D. Anderson Cancer Center. The lab was interested in the role of Caveolin-1 (Cav-1), a Src kinase substrate, as it is overexpressed in primary prostate cancer (PCa) and in PCa bone metastases. In addition, PCa-derived and -secreted Cav-1 contributes to malignant progression. Using samples from patients enrolled on a phase II clinical trial of docetaxel and dasatinib (a Src family kinase [SFK]/abl inhibitor), Dr. Carthon was able to characterize Cav-1 as a biomarker and potential target in castration-resistant prostate cancer. The team stratified responder and non-responder patient data according to patients with locally advanced vs. bone metastatic disease. In brief, their findings suggested that serum Cav-1 can serve as a novel discriminating biomarker for SFK/Abl inhibition in both node-positive and bone-metastatic castration-resistant prostate cancer. Moreover, responding patients with bone predominant prostate cancer demonstrated higher levels of serum Cav-1. In vitro data suggested that this was likely due to a direct effect of Src family kinase inhibition on osteoblasts of the bone microenvironment. Src inhibition in osteoblast cells seemed to promote osteoblast differentiation and provided rationale for the use of dasatinib as a way to target not only prostate cancer cells, but also other cells of the bone microenvironment in prostate cancer bone metastases.
1. Targeted therapeutics in locally advanced and bone metastatic prostate cancer.
2. Targeted therapies and novel therapeutic combinations in additional genitourinary malignancies (e.g. bladder, penile & renal cancers)
- View publications on Pubmed
View clinical trials at Winship Cancer Institute